NIH | Promising Interim Results from NIH-Moderna Vaccine

From the National Institutes of Health on November 16

Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine

An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 15, 2020. This interim review of the data suggests that the vaccine is safe and effective at preventing symptomatic COVID-19 in adults. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers. The DSMB reported that the candidate was safe and well-tolerated and noted a vaccine efficacy rate of 94.5%. The findings are statistically significant, meaning they are likely not due to chance. 90 of the cases occurred in the placebo group and 5 occurred in the vaccinated group. There were 11 cases of severe COVID-19 out of the 95 total, all of which occurred in the placebo group.

Continue Reading►

 

NYT | N95 Gray Market

From the New York Times on November 17

Inside the Chaotic, Cutthroat Gray Market for N95 Masks

As the country heads into a dangerous new phase of the pandemic, the government’s management of the P.P.E. crisis has left the private sector still straining to meet anticipated demand.

…But as the coronavirus rapidly rode the channels of international commerce between continents, it turned the advantages of globalization into vulnerabilities. Right when the United States needed masks most, there were severe shortages. Chinese production had ground to a halt as the country locked down to stop the virus’s spread — and just-in-time supply chains dependent on their manufacturing quickly disintegrated. Baystate Health was consuming about 15 times more respirators monthly than during pre-pandemic times, and had no easy way of finding new suppliers. It would take months for American companies to build out new production lines…

Continue Reading►

Atlantic | No One Is Listening To Us

From the Atlantic

‘No One Is Listening to Us’

Ambulance Decontamination White Paper

Published by Demers-Braun-Crestline
866-636-0415 (US)
866-667-0856 (CA)
514-971-4509 (Intl)

COVID-19 is the present-day challenge facing our first responders, but infectious diseases have always posed a threat to EMS personnel and their patients. Developed with insights and internal testing from engineering resources at Demers-Braun-Crestline, the white paper aims to identify verified solutions to reducing the spread of infectious diseases inside an ambulance. Highlighted are five key areas of focus; each is discussed in-depth to help identify why it is important and what proven options are available to implement inside an ambulance.

The white paper includes a detailed overview of each of these, helping to educate readers on ambulance options and features that assist in limiting the spread of viruses, bacteria, parasites, and fungi. From plexiglass dividers to HEPA filters, chemical fogging systems to self-disinfecting surfaces, and everything in-between, this white paper outlines a variety of solutions that every emergency response organization should consider for protecting patients and personnel from infectious diseases.

Download the White Paper online for free